SingHealth, Aussie Sirtex Ink Research Collaboration For mAb-delivering Nanoparticles
This article was originally published in PharmAsia News
Executive Summary
SingHealth’s National Cancer Center has signed a research pact with Australia-listed oncology company Sirtex to begin preclinical work on a novel biologic targeted cancer therapy to determine if the method shows efficacy in removing microscopic “tumor islands” left after surgery.